Drug application
QTERNMET XR (DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE, SAXAGLIPTIN HYDROCHLORIDE)
Drugs@FDA NDA 210874 · ASTRAZENECA AB
Key facts
| Drug name | QTERNMET XR |
|---|---|
| Active ingredients | DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE, SAXAGLIPTIN HYDROCHLORIDE |
| Application type | NDA |
| Application number | 210874 |
| Company | ASTRAZENECA AB |
| Dosage forms | TABLET, EXTENDED RELEASE, ORAL |
| Strength | 2.5MG;1GM;EQ 2.5MG BASE |
| Marketing status | Discontinued |
| Reference listed drug | Yes |
| Latest submission class | Type 4 - New Combination |
| Latest submission status date | May 2, 2019 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- 1–9 Label versions
- 1–9 Products
- None Therapeutic equivalents
- Yes FDA letters on file
- Yes FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: